The number of shares and votes in CELLINK AB (publ) (“CELLINK”) have increased as a result of a directed new issue of 57,911 shares of series B which was carried out as a part of the financing for the acquisition of Visikol Corp. The Board of Directors resolved on an issue in kind in May 2021 in accordance with the authorization from the Annual General Meeting held on April 26, 2021.
Furthermore, the number of shares and votes have increased as a result of a directed new issue of 301,332 shares of series B which was carried out as a part of the financing for the acquisition of Nanoscribe Holding GmbH. The Board of Directors resolved on an issue in kind on May 31, 2021, in accordance with the authorisation from the Annual General Meeting held on April 26, 2021.
Finally, 127,456 warrants were exercised pursuant to CELLINK’s warrant programme 2018 for subscription of 127,456 shares of series B.
Through the above-mentioned events, which the Swedish Companies Registration Office registered during June, the number of shares and votes in CELLINK increased by a total of 486,699.
As of June 30, 2021, the total number of registered and outstanding shares of CELLINK amounts to 57,064,097, of which 1,500,000 are shares of series A and 55,564,097 are shares of series B, corresponding to a total of 70,564,097 votes. The share capital amounts to SEK 1,426,602.425. The company does not hold any treasury shares.
For further information, please contact:
|Gusten Danielsson, CFO
Phone (US): +1 (857) 332 2138
Phone (Sweden): +46 709 91 86 04
|Isabelle Ljunggren, Head of Communications
Phone: +46 708 30 08 90
This is information that CELLINK AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons set out above, on June 30, 2021, at 08:00am (CEST).
Founded in 2016, CELLINK is the leading bioconvergence company in the world that provides technologies, products, and services to create, understand and master biology. With a focus on the application areas of bioprinting, multiomics, cell line development, and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. CELLINK’s products are trusted by more than 2,000 laboratories, including all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 1,700 publications. CELLINK is creating the future of medicine. CELLINK is listed on the Nasdaq the Stockholm under CLNK B. www.cellink.com